| scholarly article | Q13442814 |
| P50 | author | Harald von Melchner | Q107638157 |
| P2093 | author name string | M. Hayat | |
| P. Ribaud | |||
| G. Bonadonna | |||
| H. J. Senn | |||
| W. Mattsson | |||
| A. C. Mayr | |||
| C. G. Gallagher | |||
| C. Pollini | |||
| C. Praga | |||
| E. Villa | |||
| G. Beretta | |||
| G. De Wasch | |||
| G. R. Lenaz | |||
| K. Kolaric | |||
| L. A. Manziuk | |||
| N. I. Perevodchikova | |||
| P. L. Vigo | |||
| R. Buehner | |||
| R. Canetta | |||
| R. Castellani | |||
| R. Heinz | |||
| R. Waldner | |||
| W. Ten Bokkel-Huyninck | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| P304 | page(s) | 827-834 | |
| P577 | publication date | 1979-05-01 | |
| P1433 | published in | Cancer Treatment Reports | Q27710285 |
| P1476 | title | Adriamycin cardiotoxicity: a survey of 1273 patients | |
| P478 | volume | 63 |
| Q42196156 | Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
| Q42545207 | Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure |
| Q41464584 | Anthracycline cardiomyopathy |
| Q33974943 | Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts) |
| Q48356620 | Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core Nanocapsules as a Strategy to Target Alpha(V) Beta(3) Integrin Expressed on Tumor Cells |
| Q70237141 | Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor |
| Q38242641 | Cardiomyopathy associated with cancer therapy |
| Q72011914 | Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen |
| Q36174517 | Cardiotoxicity of cancer chemotherapy: implications for children |
| Q33903066 | Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention |
| Q41998267 | Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients. |
| Q92218673 | Chemotherapy-related Cardiomyopathy |
| Q39513605 | Clinical pharmacokinetics of doxorubicin |
| Q42961337 | Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity |
| Q92520508 | Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model |
| Q42538949 | Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy |
| Q35550223 | Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
| Q40162046 | Doxorubicin (adriamycin) cardiomyopathy |
| Q61797308 | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
| Q44389042 | Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. |
| Q39575531 | Doxorubicin cardiotoxicity: response of left ventricular ejection fraction to exercise and incidence of regional wall motion abnormalities |
| Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
| Q33985488 | Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy |
| Q35371321 | Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables |
| Q34800157 | Early identification of anthracycline cardiomyopathy: possibilities and implications |
| Q56986554 | Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis |
| Q34535269 | Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. |
| Q36153755 | Exercise capacity in apparently healthy survivors of cancer |
| Q42477415 | Hemodynamic effects of chronic 4'epi-adriamycin administration |
| Q67552716 | Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog |
| Q71662326 | M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen |
| Q41243586 | Management of Advanced Heart Failure due to Cancer Therapy: the Present Role of Mechanical Circulatory Support and Cardiac Transplantation |
| Q36410651 | Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer |
| Q36864827 | Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes |
| Q77582067 | Modulation of adriamycin-induced changes in serum free fatty acids, albumin and cardiac oxidative stress |
| Q36061374 | Multiple impairments of cutaneous nociceptor function induced by cardiotoxic doses of Adriamycin in the rat. |
| Q30427656 | Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs |
| Q35993715 | Outcome in stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL 86)--how much treatment is needed? United Kingdom Children's Cancer Study Group |
| Q40931106 | Physiological aspects of aging. Implications for the treatment of cancer |
| Q70806934 | Plasma pharmacokinetics of adriamycin after intrapleural administration |
| Q42226208 | Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. |
| Q42251045 | Possible prevention of adriamycin-induced cardiomyopathy by verapamil. Results of a pilot study |
| Q44606812 | Pregnancy outcome in women treated with doxorubicin for childhood cancer |
| Q41875965 | RGS Proteins in Heart: Brakes on the Vagus. |
| Q58556599 | Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin |
| Q34092826 | Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction |
| Q28318119 | Significance of adaptation mechanisms in adriamycin induced congestive heart failure |
| Q84010947 | Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy |
| Q69639235 | The clinical syndrome of 5-fluorouracil cardiotoxicity |
Search more.